Low rates of screening and treatment of chronic hepatitis B, C, D (HBV, HCV, HDV), and hepatocellular carcinoma (HCC), associated barriers, and proposed solutions: results of a survey of physicians from all major provinces of Mongolia

• J. Estevez,
• Y.A. Kim,
• A. Le,
• D. Israelski,
• O. Baatarkhuu,
• T. Sarantuya,
• S. Narantsetseg,
• P. Nymadawa,
• H. Le,
• M.F. Yuen,
• G. Dusheiko,
• M. Rizzetto,
• M.H. Nguyen

Affiliations

J. Estevez

Division of Gastroenterology and Hepatology at Stanford University, California, USA

Y.A. Kim

Division of Gastroenterology and Hepatology at Stanford University, California, USA

A. Le

Division of Gastroenterology and Hepatology at Stanford University, California, USA

D. Israelski

Center for Innovation In Global Health at Stanford University, California, USA

O. Baatarkhuu

Department of Infectious Diseases at Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

T. Sarantuya

Internal Medicine Department at United Family Intermed Hospital, Ulaanbaatar, Mongolia

S. Narantsetseg

The Third State Central Hospital of Mongolia, Ulaanbaatar, Mongolia

P. Nymadawa

Public Health Branch, Mongolian Academy of Medical Sciences, Ulaanbaatar, Mongolia

H. Le

Division of Gastroenterology and Hepatology at Stanford University, California, USA

M.F. Yuen

Division of Gastroenterology and Hepatology at Queen Mary Hospital, Hong Kong

G. Dusheiko

Royal Free Hospital and University College London School of Medicine in London, United Kingdom

M. Rizzetto

Department of Gastroenterology at the University of Torino, Torino, Italy

M.H. Nguyen

Division of Gastroenterology and Hepatology at Stanford University, California, USA